NLRP3 and Parkinson disease: MCC950 and miRNA-7 inhibitors, by suppressing the activation of the NLRP3 inflammasome within microglial cells, can alleviate neuroinflammation and neuronal damage associated with Parkinson’s disease, offering new potential therapeutic targets for the treatment of PD.